The mean value obtained in the questionnaire was 0.71 ± 0.19. Conclusions As has been shown in previous studies, the two dimensions of EuroQoL-5D that most affected the QoL were pain/ discomfort and anxiety/depression. No conflict of interest. Expanding thE involvEmEnt of pharmacy SErvicES via computEriSEd mEdical filES

Background Given the high budgetary impact of antiretroviral therapy (ART) and the lack of adherence to sometimes complex HIV treatment, it is interesting to analyse the reasons for changes between different ARTs. Purpose To analyse the causes of change of ART in 439 patients over 16 months (January 2012–April 2013) in a general hospital. Materials and methods Retrospective observational study included all HIV patients in the Farmatools Applicative Outpatient module version 2.4. We defined 4 reasons for change in treatment and the following variables: Treatment failure: CD4, viral load (CV). Simplification of treatment: number of pills before/after the change. Adverse effects (AEs) Other Results Of the 439 patients included, 39 patients had treatment changes, with 161 modifications. Reasons for change: 11/161 for treatment failure. The median CV and CD4 were 13,997 copies/ml and 280 cells/mcL, respectively. 98/161, for simplicity. The commercial presentation was the most common reason for change (60/98). Of the 98 patients, 64 reduced 1 tablet in treatment, 32 reduced 2 tablets and 2 patients reduced 3 tablets. The mean reduction was 1.35. (SD = 0.53) 42/161 changes because of AEs: renal toxicity (14/44 patients), lipid disorders (8/44 patients), central nervous system disorders (6/44 patients), lipoatrophy (6/44 patients), osteopenia (3/44 patients) and others (5/44 patients). 10/161, changes for other reasons. 3/161 by treatment update. 5/161 for suspected interaction with other concomitant treatments (3 interactions with triple protease inhibitor treatment for hepatitis C, 1 interaction with omeprazole and another with methadone). 1/161, for dose adjustment in renal failure, 1/161 for unknown reasons. Conclusions The main cause of treatment change was simplification, because new commercial presentations reduced the number of pills/doses or shots/day. The second and third reasons were adverse effects and treatment failure, unlike those reflected in the literature. No conflict of interest.

Eur J Hosp Pharm 2013;20(Suppl 1):A1-238 A113 using Excel. We compared clinical results pre-and post-Oc-LAR use. The x 2 test was used for category variables, and the t-test was used for continuous variables with normal distribution using SPSS statistical software. Clinical and monetary value were derived from publicly available data. The study perspective was from the hospital management point of view. Results 17 patients were included in the study, 11 were men and 6 women. The mean age was 75.2 years. The direct costs were €350 per red blood cell transfusion, €167 per iron administration and €694.95 for Oc-LAR.The mean Hb levels were 9.0 g/dl and 9.6 g/dl (p < 0.0001) before and after treatment. Blood transfusions decreased from 1.8 to 1.7 (P = 0.258). However iron requirements were higher after treatment started:. 2.5 vials of iron, up from 1.9 (P = 0.027). And there was an increase in hospital admissions annually 3.3 vs. 2.3 before treatment (P = 0.311). So Oc-LAR use increased the average annual cost per patient by 8,401.6€ without stopping disease progression. Conclusions Pharmacological treatments are typically considered in refractory cases of endoscopic failure and recurrent bleeding. Oc-LAR seems to be more suitable in terms of efficacy and tolerance according to the bibliography. However, our study shows that Octreotide long-acting formulation treatment was not cost effective and failed to stop the natural evolution of the disease.No conflict of interest. Mycophenolate mofetil/Mycophenolic Acid (MM/MA) have been used in off-label conditions to treat kidney diseases. Off-LabeL Uses Of MycOphenOLate 1-5Purpose To describe the dose and effectiveness of MM/MA in the treatment of nephritis. Materials and Methods Observational, cross-sectional study including all patients diagnosed with nephritis treated with MM/ MA in off-label conditions during July 2012.Diagnosis and dose were recorded. Serum creatinine and the value of urinary proteins were collected at the beginning of the treatment and during the month of the study. Results 22 patients were included, 14 were treated with MA and 8 with MM.Of the patients treated with MA, 50% asked to be treated for nephritis, 28.6% for lupus and 21.4% for polyarteritis nodosa. (Both the lupus and the polyarteritis nodosa were giving clinical kidney symptoms.)The usual dosage was every 12 hours (12/14), the most used dose being 360 mg (10/14).The mean serum creatinine at the beginning of treatment was 1.14 mg/dl (SD .4) and decreased to 0.95 mg/dl (SD 0.3) at the end of the study. The urinary proteins value decreased from 35.4 (SD 7.3) at the beginning of treatment to 26.2 (SD 3.2) at the end of the study.Of the patients treated with MM 62.5% requested treatment of nephritis and 37.5% of lupus. (The usual dosage was every 12 hours (7/8), the most used dose being 500 mg (3/8), 400 mg (2/8),1500 mg, 1000 mg and 250 mg (1/8).The mean serum creatinine at the beginning of treatment was 1.35 mg/dl (SD 0.6) and decreased to 1.13 mg/dl (SD 0.5) at the end of the study. The urin...